Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. Its lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; VIVUS, Inc.; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:KDMN
CUSIPN/A
Phone212-308-6000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.24%
Quick Ratio1.23%
Price-To-Earnings
Trailing P/E Ratio-2.95
Forward P/E Ratio-3.77
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.26 million
Price / Sales26.88
Cash FlowN/A
Price / CashN/A
Book Value($0.49) per share
Price / Book-8.55
Profitability
EPS (Most Recent Fiscal Year)($1.42)
Net Income$-79,770,000.00
Net Margins-650.47%
Return on EquityN/A
Return on Assets-110.26%
Miscellaneous
Employees101
Outstanding Shares78,640,000
Kadmon (NYSE:KDMN) Frequently Asked Questions
What is Kadmon's stock symbol?
Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."
How were Kadmon's earnings last quarter?
Kadmon Co. (NYSE:KDMN) issued its earnings results on Tuesday, March, 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.12. The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $3.07 million. The company's quarterly revenue was down 65.1% on a year-over-year basis. During the same period last year, the business earned ($0.50) EPS. View Kadmon's Earnings History.
What price target have analysts set for KDMN?
4 Wall Street analysts have issued 1 year price targets for Kadmon's shares. Their predictions range from $3.00 to $25.00. On average, they expect Kadmon's share price to reach $13.25 in the next twelve months. View Analyst Ratings for Kadmon.
Who are some of Kadmon's key competitors?
Some companies that are related to Kadmon include Adamas Pharmaceuticals (ADMS), Rocket Pharmaceuticals (RCKT), Rhythm Pharmaceuticals (RYTM), Lannett (LCI), Geron (GERN), Ziopharm Oncology (ZIOP), Odonate Therapeutics (ODT), Five Prime Therapeutics (FPRX), BeyondSpring (BYSI), Rigel Pharmaceuticals (RIGL), Aduro BioTech (ADRO), Kura Oncology (KURA), Arrowhead Pharmaceuticals (ARWR), Reata Pharmaceuticals (RETA), Keryx Biopharmaceuticals (KERX), Aclaris Therapeutics (ACRS), TiGenix - American Depositary Shares (TIG) and Dicerna Pharmaceuticals (DRNA).
Who are Kadmon's key executives?
Kadmon's management team includes the folowing people:
- Dr. Harlan W. Waksal, Pres, CEO & Director (Age 65)
- Mr. Konstantin Poukalov, Exec. VP & CFO (Age 34)
- Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 50)
- Mr. Charles Darder, Principal Accounting Officer & Controller
- Dr. John L. Ryan M.D., Ph.D., Chief Medical Officer and Exec. VP (Age 75)
When did Kadmon IPO?
(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Has Kadmon been receiving favorable news coverage?
News articles about KDMN stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kadmon earned a daily sentiment score of 0.07 on Accern's scale. They also gave news stories about the company an impact score of 45.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Kadmon?
Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon's stock price today?
One share of KDMN stock can currently be purchased for approximately $4.19.
How big of a company is Kadmon?
Kadmon has a market capitalization of $345.24 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe.
How can I contact Kadmon?
Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]
MarketBeat Community Rating for Kadmon (KDMN)
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kadmon (NYSE:KDMN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Kadmon in the last 12 months. Their average twelve-month price target is $13.25, suggesting that the stock has a possible upside of 216.23%. The high price target for KDMN is $25.00 and the low price target for KDMN is $3.00. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Hold | Hold | Buy |
| Consensus Rating Score: | 2.50 | 2.40 | 2.25 | 2.50 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.25 | $11.40 | $9.75 | $9.80 |
| Price Target Upside: | 216.23% upside | 201.59% upside | 172.35% upside | 159.95% upside |
Kadmon (NYSE:KDMN) Consensus Price Target History
Kadmon (NYSE:KDMN) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Kadmon (NYSE:KDMN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Kadmon (NYSE KDMN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.41%
Institutional Ownership Percentage: 61.71%
Kadmon (NYSE KDMN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/6/2017 | Goldentree Asset Management Lp | Major Shareholder | Sell | 302,950 | $2.73 | $827,053.50 | |  |
| 8/10/2017 | Harlan Waksal | CEO | Buy | 5,000 | $2.27 | $11,350.00 | 110,747 | |
| 8/8/2017 | Eugene Bauer | Director | Buy | 5,000 | $2.36 | $11,800.00 | 1,716 | |
| 8/8/2017 | Harlan Waksal | CEO | Buy | 3,707 | $2.34 | $8,674.38 | 105,747 | |
| 8/8/2017 | Steven N. Gordon | VP | Buy | 1,000 | $2.47 | $2,470.00 | | |
| 7/31/2017 | Goldentree Asset Management Lp | Major Shareholder | Sell | 349,661 | $2.60 | $909,118.60 | | |
| 7/11/2017 | Goldentree Asset Management Lp | Major Shareholder | Sell | 34,462 | $3.69 | $127,164.78 | | |
| 6/29/2017 | Goldentree Asset Management Lp | Major Shareholder | Sell | 64,375 | $4.04 | $260,075.00 | | |
| 6/27/2017 | Goldentree Asset Management Lp | Major Shareholder | Sell | 108,827 | $3.69 | $401,571.63 | | |
| 6/26/2017 | Goldentree Asset Management Lp | Major Shareholder | Sell | 515,643 | $3.51 | $1,809,906.93 | | |
| 6/22/2017 | Goldentree Asset Management Lp | Major Shareholder | Sell | 767,363 | $3.50 | $2,685,770.50 | | |
| 3/13/2017 | Daniel S Loeb | Major Shareholder | Buy | 1,488,095 | $3.36 | $4,999,999.20 | | |
| 11/16/2016 | Harlan Waksal | CEO | Buy | 2,000 | $6.37 | $12,740.00 | 102,040 | |
| 11/14/2016 | Harlan Waksal | CEO | Buy | 2,000 | $6.79 | $13,580.00 | 100,040 | |
| 11/11/2016 | Konstantin Poukalov | CFO | Buy | 4,000 | $5.81 | $23,240.00 | 1,000 | |
| 9/14/2016 | Daniel S Loeb | Major Shareholder | Buy | 19,611 | $7.79 | $152,769.69 | | |
| 9/13/2016 | Daniel S Loeb | Major Shareholder | Buy | 68,654 | $8.33 | $571,887.82 | | |
| 9/6/2016 | Daniel S Loeb | Major Shareholder | Buy | 81,781 | $9.39 | $767,923.59 | | |
| 8/26/2016 | Daniel S Loeb | Major Shareholder | Buy | 32,916 | $9.98 | $328,501.68 | | |
| 8/22/2016 | Daniel S Loeb | Major Shareholder | Buy | 11,305 | $10.00 | $113,050.00 | | |
| 8/15/2016 | Daniel S Loeb | Major Shareholder | Buy | 6,010 | $9.95 | $59,799.50 | | |
| 8/12/2016 | Daniel S Loeb | Major Shareholder | Buy | 87,529 | $9.98 | $873,539.42 | | |
| 8/5/2016 | Daniel S Loeb | Major Shareholder | Buy | 66,828 | $9.94 | $664,270.32 | | |
| 8/3/2016 | Daniel S Loeb | Major Shareholder | Buy | 1,431,996 | $11.35 | $16,253,154.60 | | |
| 8/1/2016 | Goldentree Asset Management Lp | Major Shareholder | Buy | 208,333 | $12.00 | $2,499,996.00 | | |
| 7/28/2016 | Bart M Schwartz | Director | Buy | 2,000 | $9.77 | $19,540.00 | 26,211 | |
(Data available from 1/1/2013 forward)
Kadmon (NYSE KDMN) News Headlines
| Source: |
|
Kadmon (NYSE:KDMN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kadmon (NYSE:KDMN) Income Statement, Balance Sheet and Cash Flow Statement
Kadmon (NYSE KDMN) Stock Chart for Thursday, April, 19, 2018
Loading chart…
